Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × von Hippel-Lindau Disease × belzutifan × Clear all

Phase

Status

Recruiting 2 Withdrawn 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 13 Kidney Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Glioblastoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03401788 2024-12-03

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting

50 enrolled 1 FDA

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡